For co-commercialisation agreement for SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla Biocartis Group recently announced the expansion of its partnership with Immunexpress with a co-commercialisation agreement for the SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla. The SeptiCyte RAPID Test is a rapid, host-response[1] test…

Read More

Biocartis has expanded its current partnership with Seattle-based Immunexpress by launching a co-commercialization agreement for Immunexpress’ SeptiCyte Rapid test on Biocartis’ Idylla platform. As part of the expanded collaboration, Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US. Immunexpress also noted today…

Read More
Immunexpress.com

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe   SEATTLE and BRISBANE, March 26, 2020 – Immunexpress,…

Read More

Join the Immunexpress team for a cocktail reception of Tapas & Technology, during which you can enjoy Spanish Tapas with Rioja wine and watch a demonstration of SeptiCyte™ RAPID running and generating results on the BioCartis Idylla™ platform. There will also be two short presentations. Steven P. LaRosa, MD, Infectious Disease Specialist at Beverly Hospital,…

Read More

Join us to learn about some of Immunexpress’ recent innovations. This sponsored innovation webinar will address the shortcomings of past and current sepsis clinical criteria in accurately capturing patients with critical illness due to infection. The current status of microbiologic methods and single peptide biomarker will be described. A novel approach utilizing the host gene…

Read More
Immunexpress.com

Immunexpress, Pty Ltd & Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced that it has been successfully certified according to ISO 13485:2016 & EN ISO 13485:2016, the international standard for medical device quality management systems. The scope of the certification includes the design and…

Read More

There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But there are times when it’s necessary…

Read More

Background: The ability to accurately diagnose sepsis at ICU admission is key to effective clinical management, patient safety, and efficient hospital resource utilization. Most tests used for sepsis diagnosis, including pathogen detection and host-based biomarker approaches, are lacking in either sensitivity or specificity, resulting in a clinical assumption of sepsis, patient overtreatment with antimicrobials, and…

Read More
Immunexpress.com

Immunexpress Announces Closing of Private Funding Round Funding will support the development of SeptiCyte™ RAPID through FDA 510(k) Clearance CE Marking of SeptiCyte™ RAPID anticipated in 1Q2020, FDA Clearance anticipated mid-2020 SEATTLE, Oct. 3, 2019 /PRNewswire/ — Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the closing of a major…

Read More